Safety and efficacy of barzolvolimab in adults with prurigo nodularis: A Phase 1b Study

Name: Safety and efficacy of barzolvolimab in adults with prurigo nodularis: A Phase 1b Study
Creator: Martin Metz
Published: 2025-09-19T14:59:10.148Z
Keywords: Phase I Trials

Metz, Martin; Ständer, Sonja; Moiin, Ali; Nattkemper, Leigh; Bloom, Bradley; Alvarado, Diego; Rogalski, Mark; Lu, Yufang; Hawthorne, Thomas; Bili, Androniki; Meltzer-Podolske, Michelle; Yosipovitch, Gil

doi:10.17632/nsyjyhsc2s.4

Safety and efficacy of barzolvolimab in adults with prurigo nodularis: A Phase 1b Study

Published: 19 September 2025| Version 4 | DOI: 10.17632/nsyjyhsc2s.4

Contributors:

Martin Metz, Sonja Ständer, Ali Moiin, Leigh Nattkemper, Bradley Bloom, Diego Alvarado, Mark Rogalski, Yufang Lu, Thomas Hawthorne, Androniki Bili, Michelle Meltzer-Podolske, Gil Yosipovitch

Description

Supplemental materials for brief report:Safety and efficacy of barzolvolimab, an anti-KIT monoclonal antibody, in adults with moderate-to-severe prurigo nodularis: A randomized phase 1b intravenous single-dose study

Safety and efficacy of barzolvolimab in adults with prurigo nodularis: A Phase 1b Study

Description

Files

Institutions

Categories

Funders

Licence